InvestorsHub Logo
Followers 94
Posts 2734
Boards Moderated 0
Alias Born 09/15/2020

Re: ATLnsider post# 622109

Friday, 08/18/2023 4:15:10 PM

Friday, August 18, 2023 4:15:10 PM

Post# of 689398
My views were based on deals I have seen in the industry. Granted those deals were with early stage product, where DCVax-L is very late stage.

https://news.bms.com/news/partnering/2018/Bristol-Myers-Squibb-and-Nektar-Therapeutics-Announce-Global-Development--Commercialization-Collaboration-for-Nektars-CD122-biased-Agonist-NKTR-214/default.aspx

This is just one example. This one has an added equity share involved, but prior to announcement Nektars MC was around $2B, which is where we were earlier. Funny thing is that this was a deal for combination with Opdivo. This deal was not completely exclusive and they got $1B upfront. The combination didn't work out and the deal was later terminated.

You could be right that they would keep all profits and just get paid for exclusivity.
Bullish
Bullish
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News